4-APBT

{{Infobox drug

| drug_name =

| image = 4-APBT.svg

| width =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class = Serotonin–norepinephrine–dopamine releasing agent

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number =

| CAS_supplemental =

| PubChem =

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = 4-(2-Aminopropyl)-1-benzothiophene

| IUPAC_name = 1-(1-benzothiophen-4-yl)propan-2-amine

| C=11 | H=13 | N=1 | S=1

| SMILES = CC(Cc1cccc2c1ccs2)N

| StdInChI = 1S/C11H13NS/c1-8(12)7-9-3-2-4-11-10(9)5-6-13-11/h2-6,8H,7,12H2,1H3

| StdInChIKey = NKOJSEHZOSSUEN-UHFFFAOYSA-N

}}

4-APBT, also known as 4-(2-aminopropyl)-1-benzothiophene, is a monoamine releasing agent (MRA) of the amphetamine and benzothiophene families.{{cite journal | vauthors = Brandt SD, Carlino L, Kavanagh PV, Westphal F, Dreiseitel W, Dowling G, Baumann MH, Sitte HH, Halberstadt AL | title = Syntheses and analytical characterizations of novel (2-aminopropyl)benzo[b]thiophene (APBT) based stimulants | journal = Drug Test Anal | volume = 12 | issue = 8 | pages = 1109–1125 | date = August 2020 | pmid = 32372465 | pmc = 8281332 | doi = 10.1002/dta.2813 | url = }}{{cite journal | vauthors = Rudin D, McCorvy JD, Glatfelter GC, Luethi D, Szöllősi D, Ljubišić T, Kavanagh PV, Dowling G, Holy M, Jaentsch K, Walther D, Brandt SD, Stockner T, Baumann MH, Halberstadt AL, Sitte HH | title = (2-Aminopropyl)benzo[β]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice | journal = Neuropsychopharmacology | volume = 47 | issue = 4 | pages = 914–923 | date = March 2022 | pmid = 34750565 | pmc = 8882185 | doi = 10.1038/s41386-021-01221-0 | url = }} It acts specifically as a fairly well-balanced serotonin–norepinephrine–dopamine releasing agent (SNDRA), with {{Abbrlink|EC₅₀|half-maximal effective concentration}} values of 21.2{{nbsp}}nM for serotonin, 46.2{{nbsp}}nM for norepinephrine, and 66.6{{nbsp}}nM for dopamine in rat brain synaptosomes. 4-APBT was first described in the scientific literature by 2020.